日本語 
CureApp has launched a new business called DTx-BASE, aimed at helping companies turn therapeutic apps into real, usable medical treatments. Not pilots. Not experiments. Actual products that clear regulation, get reimbursed, and reach patients.
Digital therapeutics have been talked about for years as the next wave of treatment. In reality, most teams get stuck. Clinical trials look different for software. Regulations keep shifting. Insurance coverage is unclear. Sales models do not exist yet. Compared to drugs or devices, the path is still rough.
CureApp is coming from a position of experience. It is currently the only company in Japan with multiple therapeutic apps approved by the Ministry of Health and covered by insurance. These apps target nicotine addiction, hypertension, and alcohol dependence. The company has already built the approval, reimbursement, and sales machinery that others are still figuring out.
Also Read: HPE Goes All in on AI-Native Networking and It Is Moving Fast
As digital therapeutics move closer to mainstream care, execution matters more than vision. DTx-BASE is CureApp’s attempt to standardize that execution.
English